Lamotrigine (Answer: C)
Lamotrigine is the anticonvulsant that acts by both blocking voltage-gated sodium channels to decrease sustained repetitive neuronal firing AND reducing depolarization-dependent calcium uptake.
Mechanism of Action Analysis
Lamotrigine's Dual Mechanism
Lamotrigine works through selective blockade of voltage-dependent sodium channels, which stabilizes the presynaptic neuronal membrane and inhibits sustained high-frequency repetitive firing 1, 2. Additionally, lamotrigine reduces depolarization-dependent calcium uptake by affecting T-type calcium channels, distinguishing it from other sodium channel blockers 1.
Why Not the Other Options?
Carbamazepine (Option A):
- Acts primarily through sodium channel blockade to reduce repetitive firing 1
- Does NOT significantly reduce depolarization-dependent calcium uptake as a primary mechanism
- Works by enhancing sodium channel inactivation but lacks the calcium-modulating effects described in the question
Ethosuximide (Option B):
- Specifically targets T-type calcium channels 1
- Does NOT work through sodium channel blockade
- Mechanism is limited to calcium channel modulation, missing the sodium channel component entirely
Phenobarbital (Option D):
- Enhances GABAA receptor-mediated inhibition 1
- Does NOT work through sodium channel blockade or calcium channel modulation
- Completely different mechanism from what the question describes
Clinical Context
The combination of sodium channel blockade with calcium channel effects makes lamotrigine effective across multiple seizure types. This dual mechanism explains its efficacy in both partial seizures (where it showed 20-34% responder rates at doses of 300-500 mg/day) and generalized seizures 3. The calcium-modulating effect may contribute to preventing seizure spread across neuronal networks, while the sodium channel blockade prevents the initiation of repetitive firing.
Important Caveat
When initiating lamotrigine, use slow titration to minimize the risk of serious rash (Stevens-Johnson syndrome), which occurred in up to 17% of patients in clinical trials, with one case of Stevens-Johnson syndrome reported 3. The rash risk is particularly elevated with rapid titration or concomitant valproic acid use, requiring dose reduction to 50% when combined with enzyme inhibitors 3.